Physician profile
Ashwin N Raval
NPI 1558369132
$2,214.48
in general payments reported to CMS, 2019-2025
21 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.56 · 2020: $535 · 2021: $535 · 2022: $280 · 2023: $279 · 2024: $346 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $531.51 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $214.90 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $188.10 | 2021-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $164.80 | 2019-2025 | Jardiance, Zepbound |
| Amarin Pharma, INC. | $125.86 | 2020-2021 | |
| Glaxosmithkline, LLC. | $123.93 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $122.21 | 2021 | |
| Janssen Pharmaceuticals, INC | $120.16 | 2020-2022 | |
| Pfizer INC. | $117.12 | 2019-2024 | |
| Allergan, INC. | $111.69 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.27 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.16 | 2020-2023 | Xifaxan |
| Genentech USA, INC. | $57.33 | 2019-2021 | |
| Amgen INC. | $31.62 | 2023-2025 | Otezla, Repatha, Evenity |
| Biohaven Pharmaceuticals, INC. | $29.09 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $28.31 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $26.79 | 2021-2022 | |
| Verona Pharma, INC. | $17.70 | 2025 | Ohtuvayre |
| Nestle Healthcare Nutrition INC. | $15.64 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.43 | 2021 | |
| Abbott Laboratories | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Raval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.